Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kodiak Sciences
Biotech
Kodiak resurrects eye drug after ph. 3 data renew approval plans
Kodiak Sciences gave up on tarcocimab tedromer earlier this year after a pair of phase 3 failures. A fresh batch of late-stage data has changed that.
James Waldron
Nov 6, 2023 8:40am
Kodiak's CMO hands in notice a month after pair of phase 3 fails
Aug 18, 2023 7:35am
'Unexpected' cataracts in ph. 3 end Kodiak's hopes for eye drug
Jul 24, 2023 8:58am
Kodiak asset matches Regeneron's Eylea in macular edema phase 3
Aug 8, 2022 9:53am
Kodiak's vision loss drug flops first of 6 phase 3 studies
Feb 23, 2022 10:00am
Kodiak bags $225M in exchange for $1B-plus in future royalties
Dec 2, 2019 10:40am
